Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors

British Journal of Haematology

Volumn 119, Issue 2, 2002, Pages 342-347

  Astermark, Jan ^a,b   Ekman, Maj ^a   Berntorp, Erik ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibodies; By passing agents; Factor VIIa; Haemophilia; Inhibitors

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A ANTIBODY; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 ANTIBODY; IMMUNOGLOBULIN FRAGMENT; PROTEIN A; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SEPHAROSE; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIBODY RESPONSE; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG EFFECT; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HUMAN CELL; IMMUNOAFFINITY CHROMATOGRAPHY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PURIFICATION;

ANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; BLOTTING, WESTERN; CHROMATOGRAPHY, AFFINITY; FACTOR VIIA; HEMOPHILIA A; HEMOPHILIA B; HUMANS; IMMUNE TOLERANCE; RECOMBINANT PROTEINS; THROMBIN;

EID: 0036440988     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03853.x     Document Type: Article

References (22)

1. Algiman, M., Dietrich, G., Nydegger, U.E., Boeildieu, D., Sultan, Y. & Kazatchkine, M.D. (1992) Natural antibodies to factor VIII (antihemophilic factor) in healthy individuals. Proceedings of the National Academy of Sciences of the United States of America, 89, 3795-3799.
2. Astermark, J., Sottile, J., Mosher, D.F. & Stenflo, J. (1994) Baculovirus mediated expression of the EGF-like modules of human factor IX fused to the factor XIIIa transamidation site in fibronectin. Evidence for a direct interaction between the N-terminal EGF-like module of factor IXaβ and factor X. Journal of Biological Chemistry, 269, 3690-3697.
3. Berntorp, E., Björkman, S., Carlsson, M., Lethagen, S. & Nilsson, I.M. (1993) Biochemical and in vivo properties of high purity factor IX concentrates. Thrombosis and Haemostasis, 70, 768-773.
4. Erhardtsen, E. (2000) Pharmacokinetics of recombinant activated factor VII (rFVIIa). Seminars in Thrombosis and Haemostasis, 26, 385-391.
5. Freiburghaus, C., Berntorp, E., Ekman, M., Gunnarsson, M., Kjellberg, B.M. & Nilsson, I.M. (1998) Immunoadsorption for removal of inhibitors: Update on treatments in Malmö-Lund between 1980 and 1995. Haemophilia, 4, 16-20.
6. Furie, B. & Furie, B.C. (1988) The molecular basis of blood coagulation. Cell, 53, 505-518.
7. Gallistl, S., Cvirn, G. & Muntean, W. (1999) Recombinant factor VIIa does not induce hypercoagulability in vitro. Thrombosis and Haemostasis, 81, 245-249.
8. Gilles, J.G.G. & Saint-Remy, J.M.R. (1992) Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. Journal of Clinical Investigations, 94, 1496-1505.
9. Hilgartner, M., Aledort, L., Gill, A.J. and the members of the FEIBA Study Group. (1990) Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion, 30, 626-630.
10. Ingerslev, J. (2000) Hemophilia. Strategies for the treatment of inhibitor patients. Haematologica, 85, 15-20.
11. Ingerslev, J., Thykjaer, H., Kudsk Jensen, O.K. & Fredberg, U. (1998) Home treatment with recombinant factor VIIa: Results from one centre. Blood Coagulation and Fibrinolysis, 1, s107-s110.
12. Kenet, G., Lubetsky, A., Gitel, S., Luboshitz, J., Varon, D. & Martinowitz, U. (2000) Treatment of inhibitor patients with rFVIIa: Continuous infusion protocols as compared to a single, large, dose. Haemophilia, 76, 297.
13. Key, N.S., Aledort, L.M., Beardsley, D., Cooper, G.D., Ewenstein, B.M., Gilchrist, G.S., Gill, J.C., Glader, B., Hoots, W.K., Kisker, C.T., Lusher, J.M., Rosenfield, C.G., Shapiro, A.D., Smith, H. & Taft, E. (1998) Home treatment of mild and moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thrombosis and Haemostasis, 80, 912-918.
14. Kim, H.C., McMillan, C.W., White, G.C., Bergman, G.E., Horton, M.W. & Saidi, P. (1992) Purified factor IX using monoclonal immunoaffinity technique: Clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood, 79, 568-575.
15. Lindley, C.M., Sawyer, W.T., Macik, G., Lusher, J., Harrison, J.F., Baird-Cox, K., Birch, K., Glazer, S. & Roberts, H.R. (1994) Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clinical Pharmacological Therapy, 55, 638-648.
16. Lusher, J., Ingerslev, J., Roberts, H. & Hedner, U. (1998) Clinical experience with recombinant factor VIIa. Blood Coagulation and Fibrinolysis, 9, 119-128.
17. Morfini, M., Longo, G., Berntorp, E., Cinotti, S., Filimberti, E., Messori, A., Nilsson, I.M. & Ferrini, P.R. (1993) Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate. Thrombosis Research, 71, 175-184.
18. Negrier, C., Goudemand, J., Sultan, Y., Bertrand, M., Rothschild, C., Lauroua, P. and the members of the French Feiba Study Group. (1997) Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thrombosis and Haemostasis, 77, 1113-1119.
19. Nilsson, I.M. & Hedner, U. (1976) Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scandinavian Journal of Haematology, 16, 369-382.
20. Nilsson, I.M., Freiburghaus, C., Sundqvist, S.-B. & Sandberg, H. (1984) Removal of specific antibodies from whole blood in a continuous extracorporeal system. Plasma Therapy and Transplant Technology, 5, 127-134.
21. Philippou, H., Adami, A., Lane, D.A., MacGregor, I.R., Tuddenham, E.G.D., Lowe, G.D.O., Rumley, A. & Ludlam, C.A. (1996) High purity factor IX and prothrombin complex concentrate (PCC): Pharmacokinetic trigger in PCC. Thrombosis and Haemostasis, 76, 23-28.
22. White, G.C. & Roberts, H.R. (1996) The treatment of factor VIII inhibitors: A general overview. Vox Sanguinis, 70, 19-23.